This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $300,000 to Cellergy Pharma Inc. located in Wilmington, Delaware. The funding supports research to develop an innovative antibody drug that can efficiently and specifically kill IgE-producing B cells to potentially achieve complete and durable suppression of allergy symptoms. The project aims to determine the potency of the drug in eliminating IgE-producing human cell lines and primary B cells in immunocompromised mouse models. This Phase I effort lays the groundwork for future Phase II studies to further evaluate the drug's potency and toxicity in more physiological, immunocompetent settings. The long-term goal is to develop a safe and cost-effective therapy that can provide complete and long-term relief from severe allergic diseases affecting millions of Americans.
Generated 3/4/25, 6:28 AM